In this study, we evaluate clinical outcomes of ER-low positive BCs as compared to ER-negative BCs in a monoinstitutional cohort of patients with non-metastatic ER < 10% breast cancer undergoing (neo)adjuvant chemotherapy. This evidence concerns the gene ESR1 and breast cancer.